ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriasis"

  • Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting

    High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis

    Michelle Mulder1, Juul van den Reek 2, Elke de Jong 2, Bram van Cranenbroek 2, Ruben Smeets 2, Irma Joosten 2, Xuehui He 3, Frank van den Hoogen 1, Hans Koenen 3 and Mark Wenink 1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboudumc, Njimegen, Netherlands

    Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
  • Abstract Number: 2092 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials

    Alemnew Dagnew1, Debora Rausch 2, Caroline Hervé 3, Toufik Zahaf 4 and Anne Schuind 1, 1GSK, Rockville, MD, 2GSK, Philadelphia, PA, 3GSK, Wavre, Belgium, 4GSK, Rixensart, Belgium

    Background/Purpose: The increased risk of herpes zoster (HZ) in older adults is attributable to age-related decline in immunity. In 2 pivotal studies, ZOE-50 (NCT01165177) and…
  • Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting

    No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study

    Xintong Li 1, Kathleen M Andersen2, Hsien-Yen Chang 3, G. Caleb Alexander 4 and Jeffrey Curtis 5, 1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, 4Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
  • Abstract Number: 104 • 2019 ACR/ARP Annual Meeting

    Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders

    Santosh Vishwakarma1, Gurulingappa Hallur 1, Himanshu Agrawal 1, Sharad Singh 1, Annasaheb Kalange 1, Seema Chikkur Gangadhar 1, Shuvranshu PraharaJ 1, Nafees Ahmad Quresh 1, Srikanth Kanagal Gopinath 1, Krishnakumar V 1, Sameer Mahmood 1, Rudresh G 1, Mohd Zainuddin 1, Rajendra Kristam 1, Ishtiyaque Ahmad 1, Ramachandraiah Gosu 1, Purra Buchi Reddy 1, N V S K Rao 1, Saloni Mehra 2, Jeyaraj D A 1, Takeshi Yura 1, Saravanakumar dhakshinamoorthy 1, Sriram Rajagopal 1, Dhanalakshmi Sivanandhan 3 and Sridharan Rajagopal 3, 1Jubilant Biosys, Bangalore, India, 2Jubilant Chemsys, Noida, India, 3Jubilant Therapeutics, Bangalore, India

    Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
  • Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting

    Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials

    Diamant Thaçi 1, Kristian Reich 2, Jo Lydie Lambert 3, Lars Iversen 4, Andrea Peserico 5, Ignasi Pau-Charles 6, Andrew Blauvelt7 and Christopher Griffiths 8, 1Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, 2University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, 3Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 4Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 5Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, 6Almirall R&D, Barcelona, Spain, Barcelona, Spain, 7Oregon Medical Research Center, Portland, OR, USA, Portland, OR, 8Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
  • Abstract Number: 291 • 2019 ACR/ARP Annual Meeting

    Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound

    Tania Gudu1, Ilaria Padovano 1, Hélène Gouze 2, François Vidal 1, Emmanuel Mahé 3, Leire Lara Gonzalez 4, Alexis Guyot 4, Philippe Saiag 4, Isabelle Bourgault Villada 4, Sophie Ruel-Gagné 1, Gilles Hayem 1, Félicie Costantino 5, Maxime Breban 6 and Maria-Antonietta D’Agostino 7, 1Rheumatology Department, APHP, Ambroise Paré Hospital, Boulogne Billancourt, France, 2Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, 3Dermatology Department, Victor Dupouy Hospital, Argenteuil, France, 4Dermatology Department, Ambroise Paré Hospital, Boulogne Billancourt, France, 5UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, 6UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, 7Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France

    Background/Purpose: Patient reported outcomes (PROs) reflect patients’ opinion on disease activity, impact of disease, quality of life (QoL), disability and are essential in the assessment…
  • Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting

    Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment

    Michaela Koehm1, Sarah Ohrndorf 2, Tanja Rossmanith 3, Hans-Eckhard Langer 4, Marina Backhaus 5, Gerd Burmester 6, Siegfried Wassenberg 7, Benjamin Köhler 8, Harald Burkhardt 1 and Frank Behrens 1, 1Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Fraunhofer IME-TMP, Frankfurt, Germany, 4RHIO, Düsseldorf, Germany, 5Park-Klinik Weissensee, Berlin, Germany, 6Charité—University Medicine Berlin, Berlin, Germany, 7Centre of Rheumatology, Ratingen, Germany, 8Rheumazentrum Ratingen, Ratingen, Germany

    Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
  • Abstract Number: 616 • 2019 ACR/ARP Annual Meeting

    Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort

    Mikhail Protopopov1, Fabian Proft 2, Joachim Sieper 2, Hildrun Haibel 2, Martin Rudwaleit 3 and Denis Poddubnyy 4, 1Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 3Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, 4Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

    Background/Purpose: Psoriasis is a common feature of axial spondyloarthritis (axSpA) occuring in approximately 10% of patients with axSpA. It has been presumed that such an…
  • Abstract Number: 2452 • 2019 ACR/ARP Annual Meeting

    The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients

    Lihi Eder1, Quan Li 2, Dana Jerome 3, Chandra Farrer 4, Proton Rahman 5 and Tanya N. Burry 6, 1Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 2Toronto Western Hospital, Toronto, Canada, 3University of Toronto, Toronto, 4University of Toronto, Toronto, Canada, 5Memorial University, Newfoundland, NL, Canada, 6Memorial University, St. Johns, Canada

    Background/Purpose: Improved understanding of the complex genetic architecture of PsA along with the reduction in the cost of genetic testing provide an opportunity to assess…
  • Abstract Number: 823 • 2019 ACR/ARP Annual Meeting

    The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study

    Lingyi Li1, Na Lu 1, Eric Sayre 1, Hui Xie 2, Diane Lacaille 3, John Esdaile 4 and J. Antonio Avina-Zubieta 5, 1Arthritis Research Canada, Vancouver, BC, Canada, 2Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
  • Abstract Number: 2463 • 2019 ACR/ARP Annual Meeting

    Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis

    Eric Toussirot1, Francois Aubin 1, maxime Desmarets 1, Daniel WENDLING 2, benoit Augé 3, jerome Gillard 4, olivier messica 4, Xavier Guillot 1, caroline Laheurte 5, elisabeth monnet 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2Rheumatology, University Teaching Hospital (CHRU), Besançon, France, 3private office, besancon, France, 4Centre Hospitalier, Lons le Saunier, France, 5EFS, besancon, France

    Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV)…
  • Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting

    C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility

    Fatima Abji1, Anastasiya Muntyanu 2, Remy Pollock 1, Rohan Machhar 1, Justine (Yang) Ye 3, Vinod Chandran 4 and Dafna Gladman 5, 1Krembil Research Institute, University Health Network, Toronto, Canada, 2University of Toronto, University Health Network, Toronto, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, Canada, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
  • Abstract Number: 2481 • 2019 ACR/ARP Annual Meeting

    Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

    Iñigo Gonzalez-Mazon1, Lara Sanchez-Bilbao 2, Natalia Palmou-Fontana 1, DAVID MARTINEZ-LOPEZ 3, Mónica Calderón-Goercke 4, DIANA PRIETO- PENA 1, Susana Armesto-Alonso 3, Miguel A Gonzalez-Gay 2 and Ricardo Blanco 2, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 4Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to…
  • Abstract Number: 1011 • 2019 ACR/ARP Annual Meeting

    Single Cell RNA Sequencing of Patients with Psoriatic Disease

    Rohan Machhar1, Kun Liang 2, Remy Pollock 1 and Dafna Gladman 3, 1Krembil Research Institute, University Health Network, Toronto, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Krembil Research Institute, U of Toronto, Toronto, ON, Canada

    Background/Purpose: Delayed diagnosis of psoriatic arthritis (PsA) can lead to poor clinical outcomes. A large proportion of PsA patients remain undiagnosed due to a lack…
  • Abstract Number: 2485 • 2019 ACR/ARP Annual Meeting

    Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy

    Angela Gupta1, Sofi Damjanovska 2, David Zidar 3, Donald Anthony 4 and Maya Mattar 3, 1Case Western Reserve University, Cleveland, 2Case Western Reserve University, Cleveland Heights, OH, 3Louis Stokes Cleveland VA Medical Center, Cleveland, OH, 4Case Western Reserve University, Cleveland, OH

    Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology